Genenta Science S.p.A. American Depositary Shares
GNTA
Closed
$1.49
Closed
-(-)
At close
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply
About
Genenta Science SpA is an early-stage company, which engages in the development of first-in-class cell and gene cancer therapies. The company is headquartered in Milan, Milano and currently employs 9 full-time employees. The company went IPO on 2021-12-15. The firm focuses on the development of lentivirus-based gene and cell therapies in cancer. The company uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The firm not only operates locally but also is present in global markets, including the United States.
Key stats
Open
$1.66
Volume
41.64K
Market cap
$40.99M
Prev. close
$1.50
Impl / hst vl
-
Open interest
$0.00
$1.48
Day’s Range
$1.66
$0.55
52W Range
$2.58
Valuation
33
Valuation score
Overvalued
P/E
-
P/S
-
P/B
1.44
Current ratio
14.16
Debt / Equity
0.10
ROE
-38.46%
Gross margin
-
Income growth
-29.36%
FCF growth
-75.50
Analysts estimates
Consensus rating
Buy
The average rating from top 4 analysts indicates that stock is expected to perform in line with the market
Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$7.14
The top 3 analysts forecasts that 12-month price may increase by 379.19%, with a low of $7.07 and a high of $7.35
$7.07
Low
$7.14
Avg
$7.35
High
Current price
Earnings
Q4 ‘25 revenue
$0.00
Q4 ‘25 net income
-$3.09M
Revenue
Net income
Explore the Healthcare sector
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply